Sustained minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R): Updated results of a phase 2 study Meeting Abstract


Authors: Kazandjian, D.; Korde, N. S.; Roschewski, M.; Mailankody, S.; Morrison, C.; Manasanch, E. E.; Kwok, M. L.; Tageja, N.; Bhutani, M.; Zingone, A.; Costello, R.; Zhang, Y.; Mulquin, M.; Lamping, L.; Carpenter, A.; Roberson, B.; Maric, I.; Calvo, K. R.; Braylan, R. C.; Yuan, C. M.; Stetler-Stevenson, M.; Arthur, D. C.; Lindenberg, L.; Kurdziel, K. A.; Choyke, P.; Steinberg, S. M.; Figg, W.; Wilson, W. H.; Landgren, O.
Abstract Title: Sustained minimal residual disease negativity in newly diagnosed multiple myeloma (NDMM) patients treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) followed by 2 years of lenalidomide maintenance (CRd-R): Updated results of a phase 2 study
Meeting Title: 58th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 128
Issue: 22
Meeting Dates: 2016 Dec 3-6
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2016-12-02
Language: English
ACCESSION: WOS:000394452505051
PROVIDER: wos
Notes: Meeting Abstract: 4527 -- Source: Wos